Although both regorafenib and DC-101 (VEGFR2 receptor inhibitor) inhibit tumor angiogenesis, regorafenib induces tumor infiltration by CD4+ and IFN-γ+CD8+T cells, which is associated with better antitumor efficacy (113). Here, CD8A is linked to neoplasm.